AI Article Synopsis
- Recent studies indicate that the cyclin-dependent kinase (CDK) pathway could be a promising target for treating brain metastases (BM).
- The interim analysis of a trial shows that the CDK inhibitor palbociclib is effective for patients with progressive BM that have CDK alterations.
- The findings support the importance of molecular testing on archived BM tissue to help choose targeted therapies that can penetrate the central nervous system (CNS).
Article Abstract
Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644914 | PMC |
| http://dx.doi.org/10.1038/s43018-021-00198-5 | DOI Listing |
Publication Analysis
Top Keywords
brain metastases
8
cyclin-dependent kinase
8
palbociclib demonstrates
4
demonstrates intracranial
4
intracranial activity
4
activity progressive
4
progressive brain
4
metastases harboring
4
harboring cyclin-dependent
4
kinase pathway
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!